|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Sage Therapeutics, Inc. (SAGE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
58,290,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sage Therapeutics is a biopharmaceutical company focused on developing and commercializing medicines with the potential to transform the lives of people with debilitating disorders of the brain. Co.'s principal product, ZULRESSO, is a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Co.'s other product candidate is zuranolone (SAGE-217), an oral compound being developed for certain affective disorders, including major depressive disorder, and PPD. Co. has a portfolio of other compounds that target GABAA receptors, including SAGE-324. SAGE-324 is a GABAA receptor positive allosteric modulator intended for chronic oral dosing.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
3,000 |
25,500 |
| Total Buy Value |
$0 |
$0 |
$87,779 |
$839,364 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
2 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
11,643 |
| Total Sell Value |
$0 |
$0 |
$0 |
$519,413 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Frates James M |
|
– • – |
2019-01-23 |
4 |
AS |
$134.81 |
$1,011,075 |
D/D |
(7,500) |
4,235 |
|
- |
|
| Frates James M |
|
– • – |
2019-01-23 |
4 |
OE |
$8.92 |
$66,900 |
D/D |
7,500 |
11,735 |
|
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2019-01-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
825 |
94,137 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2019-01-09 |
4 |
OE |
$0.45 |
$4,500 |
D/D |
10,000 |
62,115 |
|
- |
|
| Frates James M |
|
– • – |
2018-08-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
765 |
4,235 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2018-06-19 |
4 |
OE |
$0.45 |
$360 |
D/D |
800 |
26,826 |
|
- |
|
| Frates James M |
|
– • – |
2018-05-08 |
4 |
AS |
$154.00 |
$1,078,000 |
D/D |
(7,000) |
5,000 |
|
- |
|
| Frates James M |
|
– • – |
2018-05-08 |
4 |
OE |
$8.92 |
$62,440 |
D/D |
7,000 |
12,000 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2018-04-26 |
4 |
AS |
$141.21 |
$1,843,214 |
D/D |
(12,782) |
25,563 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2018-04-25 |
4 |
AS |
$140.38 |
$1,550,810 |
D/D |
(11,018) |
38,345 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2018-04-24 |
4 |
AS |
$141.51 |
$714,185 |
D/D |
(5,000) |
49,363 |
|
- |
|
| Iguchi Kimi |
CFO & Treasurer |
• – – |
2018-04-23 |
4 |
AS |
$142.84 |
$1,753,302 |
D/D |
(12,135) |
54,363 |
|
- |
|
| Starr Kevin P |
Director |
– • – |
2018-04-18 |
4 |
S |
$168.28 |
$4,038,650 |
D/D |
(24,000) |
302,817 |
|
- |
|
| Starr Kevin P |
Director |
– • – |
2018-04-17 |
4 |
S |
$169.25 |
$5,923,600 |
D/D |
(35,000) |
326,817 |
|
- |
|
| Paul Steven M |
|
– • – |
2018-03-06 |
4 |
AS |
$172.00 |
$9,999,908 |
D/D |
(58,139) |
632,712 |
|
- |
|
| Starr Kevin P |
Director |
– • – |
2018-02-16 |
4 |
D |
$0.00 |
$0 |
I/I |
(510,554) |
37,362 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2018-01-12 |
4 |
OE |
$0.45 |
$9,000 |
D/D |
20,000 |
22,948 |
|
- |
|
| Kanes Stephen |
Chief Medical Officer |
• – – |
2018-01-10 |
4 |
AS |
$170.67 |
$7,795,837 |
D/D |
(44,000) |
2,948 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2017-12-22 |
4 |
AS |
$155.00 |
$1,976,715 |
D/D |
(12,753) |
1,226 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2017-12-22 |
4 |
OE |
$0.45 |
$5,739 |
D/D |
12,753 |
13,979 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2017-12-21 |
4 |
AS |
$155.48 |
$33,102,661 |
D/D |
(210,247) |
1,226 |
|
- |
|
| Jonas Jeffrey M |
President & CEO |
• • – |
2017-12-21 |
4 |
OE |
$0.45 |
$49,611 |
D/D |
110,247 |
211,473 |
|
- |
|
| Robichaud Albert |
Chief Scientific Officer |
• – – |
2017-12-14 |
4 |
AS |
$156.31 |
$9,565,957 |
D/D |
(60,000) |
94,259 |
|
- |
|
| Starr Kevin P |
Director |
– • – |
2017-09-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(545,000) |
547,916 |
|
- |
|
| Starr Kevin P |
Director |
– • – |
2017-07-18 |
4 |
AS |
$0.00 |
$0 |
I/I |
(800,000) |
1,092,916 |
|
- |
|
261 Records found
|
|
Page 6 of 11 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
